Project Grant R01DA059824
Award Date
8/15/24
Completion Date
5/31/29
Dollars Obligated
$564K
Federal Agency
National Institute on Drug Abuse
Federal Grant Program
93.279
Assistance Type
Project Grant
Place of Performance
New York, USA
Similar Awards
This federal Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), provides $722,876 to New York University School of Medicine to conduct a 5-year study characterizing complex opioid use disorder (OUD) care trajectories and outcomes following acute service utilization. The research aims to: 1) characterize real-world OUD treatment trajectories in the year following hospital encounters among treatment-naive...
The federal Project Grant award with ID DP2DA062283 was provided by the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279). The $2,542,500 grant, awarded on September 1, 2024, will support the development of novel econometric methods and a unified framework for integrating real-world evidence (RWE) to analyze inconclusive randomized controlled trials (RCTs) focused on opioid use disorder (OUD) treatments. The project, to be conducted by Weill...
This federal Project Grant award of $683,583 from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), will support research to estimate the potential impacts of four alternative methadone treatment (MT) policy scenarios in New York State. The project will use an agent-based computer simulation model to analyze how changes to MT access points, such as through OTPs, mobile units, prescribers, and pharmacies, could influence methadone...
This $385,000 Project Grant award from the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) aims to advance integrated treatment for co-occurring opioid use disorder (OUD) and alcohol use disorder (AUD) in real-world settings. The key objectives are to: Assess the effectiveness of integrated treatment approaches, including first-line medications and glucagon-like peptide-1 receptor agonists (GLP-1 RAs), for patients with co-occurring OUD...
The National Institute on Drug Abuse (NIDA) awarded a $1,994,766 Project Grant under the Drug Use and Addiction Research Programs (CFDA 93.279) to the Cambridge Public Health Commission, doing business as Cambridge Health Alliance (CHA), to assess the causal impact and equity effects of the New York State Medicaid Value-Based Payment (VBP) policy on opioid use disorder (OUD)-related outcomes. The key products and services to be delivered under this 2-year grant, which begins on August 1, 2024,...
This federal Project Grant award, valued at $882,816.00 and provided by the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279), supports research aimed at advancing patient-centered approaches to understanding and treating co-occurring post-traumatic stress disorder (PTSD) and substance use disorders (SUDs). The key objectives of this 4-year project are to: 1) conduct new analyses on recovery-focused outcomes to evaluate the comparative...
This Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), provides $400,000 to Mountainpass Technology LLC to develop and evaluate a customized version of the "MyTrials" remote biomarker capture system for use in decentralized clinical trials (DCTs) for substance use disorders (SUDs). The key products and services to be delivered include: 1) Refinement of the existing MyTrials prototype to support the...
This Project Grant award, valued at $2,362,500 and effective from July 1, 2025 to June 30, 2029, was provided by the National Institute on Drug Abuse (NIDA) under the federal Drug Use and Addiction Research Programs (CFDA 93.279). The project aims to overcome policy and regulatory barriers that hinder access to evidence-based harm reduction and treatment services for preventing HIV transmission and overdose among people who use drugs. Key deliverables include: 1) a tool to identify policy...
This Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), is intended to design tailored harm reduction strategies to address the escalating drug overdose crisis in the United States. The $2,316,128 award, with a project period from September 15, 2024 to July 31, 2028, will support collaborative efforts with health departments and community partners across six jurisdictions (Rhode Island, Massachusetts, New York...
This $360,720 Project Grant, awarded by the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279), supports a randomized controlled trial examining the use of extended-release, injectable buprenorphine (INJ) compared to sublingual buprenorphine/naloxone (SLB) for treating opioid use disorder (OUD) in individuals who use high-potency synthetic opioids (HPSO). The primary objectives are to: 1) compare abstinence and relapse rates between the INJ...